Reddy M K, Hollenberg P F, Reddy J K
Biochem J. 1980 Jun 15;188(3):731-40. doi: 10.1042/bj1880731.
Hypolipidaemic drugs and industrial plasticizers such as di-(2-ethylhexyl) phthalate, which cause proliferation of hepatic peroxisomes, also cause an increase in an 80000-mol.wt. polypeptide in the liver of rats and mice. This polypeptide has been designated as PPA-80 (PPA, for peroxisome-proliferation-associated; 80 for 80000mol.wt.). The polypeptide PPA-80 was purified to over 90% purity from livers of rats treated with the peroxisome proliferators Wy-14,643, nafenopin, tibric acid and clofibrate by a single-step preparative sodium dodecyl sulphate/polyacrylamide-gel-electrophoretic procedure. The antibodies raised against the PPA-80 polypeptide isolated from livers of rats treated with Wy-14,643 cross-reacted with polypeptide PPA-80 purified from the livers of rats treated with Wy-14,643, as well as from the livers of rats treated with nafenopin, tibric acid and clofibrate. The anti-(polypeptide PPA-80) antibodies did not cross-react with catalase, a marker enzyme for peroxisomes, or with NADPH-cytochrome P-450 reductase, which has the same approximate mol.wt., 80000. The intensity of immunoprecipitin bands formed with microsomal, large-particle and postnuclear fractions from livers of animals pretreated with peroxisome proliferators was significantly greater compared with equal amounts of protein from corresponding fractions obtained from control animals, suggesting that these agents all enhance the synthesis of the same 80000-mol.wt. polypeptide. Although the polypeptide PPA-80 was increased in the postnuclear, large-particle and microsomal fractions of livers of rats pretreated with peroxisome proliferators, the relative abundance of this peptide in the peroxisome-rich light-mitochondrial fraction and its lack in highly purified mitochondrial fractions suggest the localization of this polypeptide in peroxisomes and/or microsomal fraction. Additional studies are needed to establish unequivocally the subcellular localization of the polypeptide PPA-80 and to ascertain if this polypeptide is identical with the multi-functional protein displaying enoyl-CoA hydratase and beta-hydroxyacyl-CoA dehydrogenase activities that was purified by Osumi & Hashimoto [(1979) Biochem. Biophys. Res. Commun.89, 580-584].
降血脂药物以及工业增塑剂,如邻苯二甲酸二(2-乙基己基)酯,可导致肝脏过氧化物酶体增殖,同时也会使大鼠和小鼠肝脏中一种分子量为80000的多肽增加。这种多肽被命名为PPA-80(PPA代表过氧化物酶体增殖相关;80代表分子量80000)。通过一步制备性十二烷基硫酸钠/聚丙烯酰胺凝胶电泳程序,从用过氧化物酶体增殖剂Wy-14643、安妥明、降脂丙酯和氯贝丁酯处理的大鼠肝脏中,将多肽PPA-80纯化至纯度超过90%。用从经Wy-14643处理的大鼠肝脏中分离出的PPA-80多肽制备的抗体,与从经Wy-14643处理的大鼠肝脏以及经安妥明、降脂丙酯和氯贝丁酯处理的大鼠肝脏中纯化的多肽PPA-80发生交叉反应。抗(多肽PPA-80)抗体与过氧化物酶体的标记酶过氧化氢酶或分子量相近(约80000)的NADPH-细胞色素P-450还原酶不发生交叉反应。与从对照动物相应部分等量蛋白质相比,用过氧化物酶体增殖剂预处理的动物肝脏微粒体、大颗粒和核后部分形成的免疫沉淀带强度明显更大,这表明这些药物均增强了同一种分子量为80000的多肽的合成。尽管在用过氧化物酶体增殖剂预处理的大鼠肝脏的核后、大颗粒和微粒体部分中多肽PPA-80有所增加,但这种肽在富含过氧化物酶体的轻线粒体部分中的相对丰度以及在高度纯化的线粒体部分中的缺失,表明该多肽定位于过氧化物酶体和/或微粒体部分。需要进一步研究来明确确定多肽PPA-80的亚细胞定位,并确定该多肽是否与大见和桥本([(1979)生物化学与生物物理学研究通讯89, 580 - 584])纯化的具有烯酰辅酶A水合酶和β-羟酰辅酶A脱氢酶活性的多功能蛋白相同。